amaxa eNews #4 amaxa biosystems
  Issue:
Article:
ContactLegal
Meetings & Shows December 2007 - June 2008


Visit amaxa at one of the following meetings & shows:


December 2007

December 1 - 5
ASCB 2008
Booth #638
amaxa Breakfast Workshop: Tuesday, December 4, 7:00 am-9:00 am
Washingtion, DC
www.ascb.org/meetings

December 10 - 12
Genes & Cancer
University of Warwick
Coventry, UK
http://science.cancerresearchuk.org/genes_and_cancer/home/



January 2008

January 23 - 26
Apoptosis World 2008 - From mechanisms to applications
European Congress Centre
Luxembourg
www.transduction-meeting.lu/index.html



February 2008

February 10 - 13
ARABLAB 2008
Booth #468
Dubai, United Arab Emirates
www.arablab.com



March 2008

March 13 - 14
RNAi 2008
Oxford, UK
www.libpubmedia.co.uk/Conferences/RNAi2008



April 2008

April 1 - 4
Analytica
Booth #211
Munich, Germany
www.analytica-world.com

April 5 - 9
Experimental Biology 2008
Booth #638
amaxa Workshop: Monday, April 7
San Diego, USA
www.eb2008.org

April 12 - 16
AACR 2008
San Diego, USA
www.aacr.org



June 2008

June 11 - 14
ISSCR 2008
Philadelphia, USA
www.isscr.org

To top

Subscribe

Subscribe here to receive future issues of amaxa eNews.
Invite a friend

Recommend amaxa's eNews to a friend or colleague.

The Nucleofector Technology, comprising Nucleofection Process, Nucleofector Device, Nucleofector Solutions, Nucleofector 96-well Shuttle System and Nucleocuvette plates and modules is covered by patent and/or patent pending rights owned by amaxa AG.

amaxa, Nucleofector, nucleofection, maxGFP, 96-well Shuttle and Nucleocuvette are either registered trademarks or trademarks of amaxa AG in the U.S. and/or Germany and/or other countries. Other product and company names mentioned herein are the trademarks of their respective owners.

amaxa disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, safety, or suitability of the information provided in this e-newsletter for any particular purpose. Any use of the information contained on any page of this e-newsletter is evidence of agreement with these terms of use.